424 related articles for article (PubMed ID: 33158765)
1. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
2. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
6. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Lim E; Waller D; Lau K; Steele J; Pope A; Ali C; Bilancia R; Keni M; Popat S; O'Brien M; Tokaca N; Maskell N; Stadon L; Fennell D; Nelson L; Edwards J; Tenconi S; Socci L; Rintoul RC; Wood K; Stone A; Muthukumar D; Ingle C; Taylor P; Cove-Smith L; Califano R; Summers Y; Tasigiannopoulos Z; Bille A; Shah R; Fuller E; Macnair A; Shamash J; Mansy T; Milton R; Koh P; Ionescu AA; Treece S; Roy A; Middleton G; Kirk A; Harris RA; Ashton K; Warnes B; Bridgeman E; Joyce K; Mills N; Elliott D; Farrar N; Stokes E; Hughes V; Nicholson AG; Rogers CA;
Lancet Respir Med; 2024 Jun; 12(6):457-466. PubMed ID: 38740044
[TBL] [Abstract][Full Text] [Related]
7. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
8. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
9. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
[TBL] [Abstract][Full Text] [Related]
10. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
14. Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
Migliore M; Calvo D; Criscione A; Palmucci S; Fuccio Sanzà G; Caltabiano R; Spatola C; Privitera G; Aiello MM; Parra HS; Ciancio N; Di Maria G
Future Oncol; 2015; 11(24 Suppl):19-22. PubMed ID: 26638918
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
Marulli G; Faccioli E; Bellini A; Mammana M; Rea F
Expert Rev Respir Med; 2017 Aug; 11(8):649-660. PubMed ID: 28580813
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
17. Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK; Jackson A; Sidhu C
JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) Protocol.
Kuribayashi K; Igeta M; Daimon T; Ibu M; Suna S; Okamoto R; Kijima T
Oncology; 2023; 101(4):257-261. PubMed ID: 36566745
[TBL] [Abstract][Full Text] [Related]
19. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
[TBL] [Abstract][Full Text] [Related]
20. [Malignant pleural mesothelioma: The role of surgery].
Fournel L; Janet-Vendroux A; Canny-Hamelin E; Mansuet-Lupo A; Guinet C; Bobbio A; Damotte D; Alifano M
Rev Pneumol Clin; 2018 Oct; 74(5):351-358. PubMed ID: 30316650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
